Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Oct 1.

Published in final edited form as: Prev Med. 2021 May 23;151:106623. doi: 10.1016/j.ypmed.2021.106623

Figure 2: — percentage of additional cancer cases over 2020–2030 in each age group*, by setting and extent of disruption (12-month scenarios)

* Age = age in 2020, not necessarily at the time of cancer diagnosis.

Results for the US represent the midpoint of results for the two included models (Harvard and Policy1-Cervix). Model-specific US results are included in an Appendix (Figure A4). All US models reflect the recommendation that women aged 21–29y be screened with 3y cytology.

Figure 2: — percentage of additional cancer cases over 2020–2030 in each age group*, by setting and extent of disruption (12-month scenarios)

* Age = age in 2020, not necessarily at the time of cancer diagnosis.

Results for the US represent the midpoint of results for the two included models (Harvard and Policy1-Cervix). Model-specific US results are included in an Appendix (Figure A4). All US models reflect the recommendation that women aged 21–29y be screened with 3y cytology.